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Abstract
Rationale:  Thrombocytopenia is a platelet associated process that occurs in human and animals
as result of i) decreased production; ii) increased utilization; iii) increased destruction coupled to
the presence of antibodies, within a process know as immune-mediated thrombocytopenia (IMT);
or iv) platelet sequestration. Thus, the differentiation of the origin of IMT and the development of
reliable diagnostic approaches and methodologies are important in the clarification of IMT
pathogenesis. Therefore, there is a growing need in the field for easy to perform assays for
assessing platelet morphological characteristics paired with detection of platelet-bound IgG.
Objectives:  This study is aimed to develop and characterize a single color flow cytometric assay
for detection of platelet-bound IgG in horses, in combination with flow cytometric assessment of
platelet morphological characteristics.
Findings:  The FSC and SSC evaluation of the platelets obtained from the thrombocytopenic
animals shows several distinctive features in comparison to the flow cytometric profile of platelets
from healthy animals. The thrombocytopenic animals displayed i) increased number of platelets
with high FSC and high SSC, ii) a significant number of those gigantic platelets had strong fluorescent
signal (IgG bound), iii) very small platelets or platelet derived microparticles were found significantly
enhanced in one of the thrombocytopenic horses, iv) significant numbers of these microplatelet/
microparticles/platelet-fragments still carry very high fluorescence.
Conclusions:  This study describes the development and characterization of an easy to perform,
inexpensive, and noninvasive single color flow cytometric assay for detection of platelet-bound IgG,
in combination with flow cytometric assessment of platelet morphological characteristics in horses.
Introduction
Thrombocytopenia is a process that occurs in humans
and animals as result of i) decreased bone marrow plate-
let production; ii) increased platelet utilization; iii) in-
creased peripheral platelet destruction; or iv) platelet
sequestration [1,2]. Thus, a differentiation of the origin
of thrombocytopenia is important for defining the prog-
nosis of the disease and the management of clinical pa-
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tients. The hallmarks of immune-mediated
thrombocytopenia (IMT) are: i) enhancement of platelet
destruction occurs which leads to a decrease in the
number of peripheral thrombocytes and ii) the presence
of antibodies associated to platelets. The antibodies,
mainly of immunoglobulin G (IgG) class, bind to the sur-
face of the platelets and result in premature platelet de-
struction [2] IMT in horses may be primary (idiopathic
thrombocytopenic purpura) [3,4], or secondary to an-
other disorder [1,5,6,7,8]. IMT has been associated with
equine infectious anemia virus (EIA) [8]. In this disease,
there is immune complex consisting of EIA virus parti-
cles and antibodies which deposit on the platelets [5,7].
In addition, IMT featured a lack of compensatory meg-
akaryocytopoiesis, which at the end contributed to the
development of thrombocytopenia [9]. IMT has also
been documented in horses with lymphosarcoma [6],
and as an idiopathic disorder [1].
Important clinical signs in horses with IMT are mucosal
petechiae, bleeding and mild dependent edema. The di-
agnosis is based on clinical signs, especially petechiae,
presence of anemia, severe thrombocytopenia, increased
mean platelet volume, platelet clumping, normal pro-
thrombin time and activated partial thromboplastin time
[7]. The bone marrow aspirates in IMT varied from nor-
mal to increase number of megakaryocytes [9]. In addi-
tion to the standard clinical and laboratory evaluation in
cases of thrombocytopenia, it is critical to assess the
presence of platelet-associated Immunoglobulin (PaIg)
since patients suffering either autoimmune diseases like
lupus erithematous or IMT have PaIg [10]. In humans,
IMT has been assessed by flow cytometry. The flow ap-
proach has been used to detect PaIg by measurement of
total IgG (including IgG contained in alpha-granules)
[11], or surface IgG which is less than 1 percent of the to-
tal PaIg in normal subjects. Both fractions are usually in-
creased in patients with IMT. However, total IgG also is
increased in patients with non-immune thrombocytope-
nia (NIT) [12,13]. Unfortunately, the flow measurement
of platelet-associated Ig only measures total Ig which
may not be specific for immune-mediated disease. A test
specific for immune-mediated disease, specifically in the
context of drug-induced autoimmune thrombocytope-
nia, is not available through flow cytometry.
The current protocol for assessing PaIg in human sub-
jects is a two color staining of fixed platelets. In brief,
platelet-rich plasma is centrifuged. Then, the pelleted
platelets are washed and fixed. Thereafter, a two-color
flow cytometry approach is used. During the cytometric
data acquisition, the platelets are gated and the mean
fluorescence intensity (MFI) of the gated cells is deter-
mined. Such MFI represents a relative measure of the
bound Ig. This MFI data can be reported like raw data or
a more sophisticated analysis can be performed by using
a standard curve, obtained after measurement the MFI
for the sample compare to a mixture of fluorescent beads
with varying amounts of fluorescent activity. Thus, in
this approach the results are actually expressed as fluo-
rescence equivalents, rather than the raw MFI values
[10,13].
The purpose of the study reported here was to develop
and characterize a single color flow cytometric assay for
detection of platelet-bound IgG in horses in combination
with flow cytometric assessment of platelet morphologi-
cal characteristics.
Materials and Methods
Cases
Two horses with epistaxis caused by thrombocytopenia
are described. In both cases primary immune mediated
thrombocytopenia was diagnosed. Other disorders that
could lead to thrombocytopenia were excluded based on
clinical examination, endoscopy of the upper and lower
respiratory system, radiographic examination of the
head, hematology and blood chemistry, and determina-
tion of the coagulation parameters: i) activated partial
thromboplastin time (aPTT), ii) thrombin time (TT) and
iii) prothrombin time (PT). Serum protein electrophore-
sis, abdominal paracentesis, abdominal ultrasonogra-
phy, biopsy of liver and spleen, bone marrow aspiration,
serologic testing and TaqMan® PCRa of Ehrlichiosis (E.
phagocytophila genogroup), and serologic testing of EIA
and Equine virus arthritis (EVA) were also performed.
Horse 1 was treated with dexamethasone (0.2 mg/kg
bwt, i.v, once daily for 10 days) and did not respond to
therapy. Horse 2 was treated with prednisolone (2 mg/kg
bwt, p.o., once daily for 10 days). The thrombocyte count
returned within three days to a normal level.
Platelet samples
Negative-control platelets used in the development of
the assay were obtained from eight healthy adult horses
that underwent physical examination, and had normal
hemograms, and biochemical analysis. Samples were ob-
tained from two horses showing signs of thrombocytope-
nia. Horse 1 had a platelet count of 70,000 µl. The bone
marrow examination showed normal cell density, active
erythropoiesis and normal megakaryocyte number.
Horse 2 had a platelet count of 15,000 µl. Activated meg-
akaryocytopoiesis and hyperplasia of plasmocytes were
observed on the examination of the bone marrow aspi-
rate. Both horses had normal serum protein concentra-
tion without hypergammaglobulinemia.
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Table 1: Percentage of platelets-FITC positive detected within the markers (M2, M3 and M4) in normal- or thrombocytopenic-horses 
inside the gate R1. Underlined are the thrombocytopenic horse values that differed by more than 1 SD with the healthy horses
R1 1a 2 3 4 5 6 7 8 9 10 1b 1c
% of all at R1 47.4 46.8 88.0 89.2 87.0 90.0 92.5 92.5 93.0 86.5 86.1 82.5 89.8 ± 2.6
% of M2 3.4 0.8 0.6 0.6 0.9 1.1 1.4 1.1 0.9 0.9 0.8 1.8 0.9 ± 0.2
% of M3 28.6 40.0 83.7 85.0 85.7 87.7 89.9 88.1 90.7 78.1 66.2 70.8 86.1 ± 4.0
% of M4 13.7 6.0 3.6 3.7 0.3 1.0 0.7 3.4 1.3 5.7 18.2 6.0 2.4 ± 1.9
*Mean ± SD of healthy horses (3-10)
Table 2: Percentage of platelets-FITC positive detected within the markers (M2, M3 and M4) in normal- or thrombocytopenic-horses 
inside the gate R2. Underlined are the thrombocytopenic horse values that differed by more than 1 SD with the healthy horses
R2 1a 2 3 4 5 6 7 8 9 10 1b 1c
% of all at R2 31.4 49.3 3.0 4.5 8.9 8.4 4.9 4.9 5.3 1.9 10.8 14.9 5.2 ± 2.4
% of M2# 4.8 6.4 1.3 2.0 2.4 7.5 3.8 3.4 3.8 1.2 2.4 6.7 3.1 ± 2.0
% of M3# 5.0 5.5 1.0 1.1 2.4 0.7 0.5 1.1 1.2 0.6 3.5 2.4 1.1 ± .6
% of M4 19.8 35.7 0.6 1.2 4.1 0.3 0.5 0.3 0.3 0.1 4.0 5.3 0.9 ± 1.3
*Mean ± SD of healthy horses (3-10). #: 4.8 + 5 = 9.8% (horse 1a) and 6.4 + 5.5 = 11.9% (horse 2)
Table 3: Percentage of platelets-FITC positive detected within the markers (M2, M3 and M4) in normal- or thrombocytopenic-horses 
inside the gate R3. Underlined are the thrombocytopenic horse values that differed by more than 1 SD with the healthy horses
R3 1a 2 3 4 5 6 7 8 9 10 1b 1c
% of all at R3 16.9 2.6 7.9 5.3 2.7 2.1 3.2 2.9 2.6 10.6 3.6 3.0 4.7 ± 3.0
% of M2 1.6 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 ± 0.03
% of M3 1.7 0.6 2.9 2.1 1.6 0.8 1.8 1.4 1.2 2.9 1.0 1.5 1.8 ± .75
% of M4 6.8 1.6 4.6 3.0 1.0 1.0 1.2 1.3 1.4 5.9 2.1 1.1 2.4 ± 1.9
*Mean ± SD of healthy horses (3-10)
Table 4: Mean Fluorescence intensity (MFI) of platelets-FITC positive detected within the gate R1, R2 and R3 in normal- or thrombo-
cytopenic-horses. Underlined are the thrombocytopenic horse values different by more than 1 SD to the healthy horses
MFI 1a 2 3 4 5 6 7 8 9 10 1b 1c
MFI at R1 436 111 96 93 145 139 136 112 115 91 69 132 116 ± 21.8
MFI at R2 702 246 654 815 425 814 1197 1026 841 1440 403 496 901.5 ± 316
MFI at R3 312 236 54 87 70 87 174 58 56 40 42 120 78.4 ± 42
*Mean ± SD of healthy horses (3-10)
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Laboratory procedures
Blood was collected by jugular venipuncture into 4.5-ml-
vacutainer tubes containing K3EDTA
b and samples were
immediately processed. Of note, since all the samples
were collected in similar conditions, the differences be-
tween healthy and sick horses can not be due to the pres-
ence of EDTA. Platelet-rich plasma was obtained by use
of centrifugation of anticoagulated blood at 300 g for 5
minutes, at room temperature (RT). Platelets were pel-
leted by centrifugation at 300 g for 20 minutes, at RT.
The platelet pellet was resuspended and washed 3 times
in 2 ml of PBS (0.15 M NaCl, 0.01 M Na2HPO4, and pH
7.4). After a third wash, the supernatant was discarded
and the platelet pellet was resuspended in 250 µl of goat
IgG anti-equine IgG conjugated to fluorescein-5-isothio-
cyanate (FITC)c diluted in PBS (dilution 1:50). The sam-
ples were incubated for 45 minutes at 37°C in the dark.
The platelets were subsequently washed 3 times with
PBS, resuspended carefully in 2 ml of 0.5% paraformal-
dehyde diluted in PBS, and analyzed for fluorescence.
The horses were bled for the flow cytometry analysis pri-
or to receiving treatment. Horse 1 was followed up and 11
days later a new flow cytometry analysis of platelets was
performed. This horse had just received a 10 days cycle of
treatment. Moreover, Horse 1 suffered a new episode of
thrombocytopenia on Dec 20, 2000. A follow up sample
was taken on January 16, 2001 (approximately two
weeks after therapy). Horse 2 was not available for follow
up studies.
Figure 1
Flow cytometric representation of morphological and fluorescent 1 (FL 1) signal of platelets. (No gate). Density
plots of ungated platelets from normal and thrombocytopenic horses. A set of panels displaying the FSC × SSC density plot of
platelets derived from three healthy horses are shown in the right panels of figure 1a. The left set of panels of figure 1b repre-
sents the FSC × SSC density plots of thrombocytopenic animals. The gates R1, R2 and R3 are showed in each panel.
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Flow Cytometric analysis
The platelet morphological characteristics and Platelet-
bound IgG (PaIg) was determined by evaluating platelet
cytometric features and fluorescence with a FACSCalibur
flow cytometerd. Cells (104 per sample) were analyzed in
a cytometer equipped for multiparametric and multi-
color analysis. Forward light scatter (FSC), orthogonal
scatter (SSC) and fluorescence were determined. Cells
were acquired and gated by FSC and SSC. An acquisition
gate (R1) containing >90% washed normal equine plate-
lets but excluding leukocytes and erythrocytes was
drawn around the platelet cloud. This acquisition gate
was used on subsequent analysis of the samples. Two ad-
ditional gates were drawn in order to analyze additional
groups of platelets (R2 was defined by high FSC and
High SSC, and R3 was defined by low FSC and medium
SSC). The gated cells were analyzed in a histogram dis-
playing the FITC expression collected in Fluorescence 1
(green channel). FSC and SSC and the fluorescent signals
were collected and storage as list mode files. Flow cytom-
etry measurement of platelets obtained from healthy
horses were also performed and used as control popula-
tions and served to determine marker borders. Using the
histogram displaying the FL-1 values from healthy horse
platelets, a region labeled M3, was set up to include most
of the events within the characteristic sharp, narrow
peak generated by normal platelets. The second region
labeled M2, was generated to include everything to the
right of the M3 region and represented platelets with in-
creased fluorescence. A fourth region, labeled M4 in-
clude most of the platelets on the left of M3 and
represented platelets with lower fluorescence. The re-
gion M1, spanned the three regions (M2, M3 and M4)
and included about 99% of the whole platelet population
within the gate. Thereafter, these regions were then ap-
plied to the histograms from thrombocytopenic horses in
order to determine the percentage of platelets positive
for FITC (FITC+) within the three gates (R1, R2, and R3)
and within the regions (M2, M3, and M4) in the sick an-
imals.
All the cytometric measurements of a Horse with IMT
and one or two healthy control Horses were performed
within a single day and under similar equipment settings
in order to avoid instrument variation. Data were ana-
lyzed with CellQuest (Becton Dickinson, San Jose Ca). In
total, eight healthy and two thrombocytopenic horses
were evaluated. Only horse one was followed up. Nega-
tive (non labeled-) and positive (labeled platelet) sam-
ples were simultaneously assayed. Negative platelets
from healthy and sick horses allowed to set up the gates
(R1, R2 and R3). Statistical analysis (mean, standard de-
viation and graphics) was performed with Microsoft Ex-
cel on a Power Macintosh computer 8500/150.
Results and Discussion
The FSC and SSC evaluation of the platelets obtained
from the thrombocytopenic animals showed quite dis-
tinctive features in comparison to the FSC and SSC pro-
file of platelets from healthy animals. Most of the
platelets from healthy animals were identified in an area
located mainly between 101-102 of the FSC axes and 101-
102 of the SSC axes. Then, this area was defined as gate
R1 (Figure 1 (no gate), right panels). Interestingly, the
thrombocytopenic animals showed two additional dis-
tinct groups of platelet clouds that prompted us to delin-
eate them by drawing two additional gates. The new
gates were labeled R2 and R3. The platelets in R2 dis-
played high FSC (>102) and High SSC (>102) and could
represent either circulating large platelets or megakary-
ocytes megathrombocytes) (Figure 1 (no gate), left pan-
els). Of note in the case of the megakaryocytes, the
maximum size of the cells included in the gate R2 dif-
fered by several orders of magnitude to the cells included
in the gate R1. Furthermore, The cloud observed in gate
R2 for the horse 2 shows two distinctive groups of cells,
(i) One with very high FSC; (ii) another with very high
SSC, which suggested great internal complexity. Inter-
estingly, horse 1 has in R2 only the cells with high FSC.
Further assays including sorting of these cells and stain-
ing with antibodies could help to clarify and define the
two groups of cells (Figure 1 (no gate), left panels). The
platelets in R3 displayed low FSC (<101) and medium
SSC (101-102) and represent either very small platelets or
platelet derived microparticles (Figure 1 (no gate), left
panels). Figure 1 overall shows that the healthy animals
(right panels) have the bulk of platelet population mainly
located in R1 (> 86%), while the thrombocytopenic ani-
mals (left panels) have < 48% (Figure 1 (no gate) and Ta-
ble 1, row: % of total within R1). In sharp contrast, the
healthy ones have only a minute platelet population lo-
cated in R2 (< 9%), whereas the sick ones have more than
31% of the total platelet counts within the R2 gate (Figure
1 (no gate) and Table 2, row: % of total within R2). Since
platelets in R2 are characterized by high FSC and high
SSC, and only the thrombocytopenic horses had signifi-
cant numbers of platelets within this gate, is likely that
the presence of circulating large platelets or megakaryo-
cytes will be tightly associated with this disease. The
presence of platelet aggregates could be another plausi-
ble explanation for the cloud observed in R2. However,
only the thrombocytopenic animals have this cloud while
the healthy ones do not. Thus, if the cloud were a com-
plex of platelet aggregates, it should be tightly associated
to the disease. Further morphological studies after sort-
ing analysis could help to clarify this issue. In addition,
one of the thrombocytopenic animals (Horse 1) showed
the presence of a significant population of platelets with
low FSC and normal SSC that represent either micro-
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thrombocytes or platelet fragments. This platelet subset
is included within the gate R3 (Figure 1 (no gate), panel:
Horse 1).
The evaluation of the presence of IgG bound to platelets
was also assessed by performing histogram analysis of
the fluorescence carried by the platelets gated into R1
(Figure 2 (Gate R1). The platelets from healthy horses
showed the characteristic sharp, narrow peak tradition-
ally described in platelets containing alpha granules. The
α-granules of platelets contains IgG, which is secreted
from platelets in response to thrombin [11,14]. The tech-
niques of platelet washing and incubation, which can
cause platelet secretion of the IgG contained within the
α-granules, may be full of critical and uncontrolled vari-
ables that affecting the measurement of platelet-bound
IgG [11]. Therefore, it would be possible that after being
released from the α-granules, IgG can bind to Fc RII
(medium affinity IgG receptor expressed in different cell
types, including platelets) on the platelet surface, leading
to misinterpretation of platelet-bound IgG measure-
ments. Thus, this peak can be mistakenly considered as
IgG bound to platelets (Figure 2 (Gate R1), right set of
panels). The marker M3 determined this peak. However,
the thrombocytopenic animals showed a clear reduction
in the height of the peak but with widening of the base as
is shown in figure 1b (Figure 2 (Gate R1), left panels). Ta-
ble 1 also showed that the percentage of platelets in M3
for the healthy animals was higher than 83% while in the
sick ones was below 40%. Within this gate, there is an in-
crease number of platelets in the sick animals, about 6%
for one horse and about 14% for the other horse that dis-
Figure 2
Flow cytometric representation of morphological and fluorescent 1 (FL 1) signal of platelets. Histogram plots of
the fluorescence signal carried by platelets delineated within gate R1.The evaluation of the presence of platelet associated IgG
(PaIg) was determined by performing histogram analysis of the fluorescence carried by the platelets gated into R1. Markers M1,
M2, M3 and M4 were drawn within the histogram plots.
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played lower levels of fluorescence signal on region M4
(Table 1). Such findings contribute to explain the widen-
ing in the base of the peak for the platelets in gate R1.
Overall, it is clear that the thrombocytopenic animals
have less platelets on the gate R1 and that those platelets
displayed lower fluorescence signal.
The set of observations found on gate R1 offered a sharp
contrast with the findings detected on gate R2. The his-
togram analysis of the fluorescence displayed by the
platelets gated into R2 from healthy animals (Figure 3
(Gate R2), right panels) showed that the normal animals
have very few platelets with high FSC and high SSC.
However, the thrombocytopenic animals displayed a
quite distinctive pattern (Figure 3 (Gate R2), left panels).
The profile displayed a peak in M4 that included a signif-
icant proportion of the platelets of the gate R2. However,
the M4 fluorescence peak was located in the zone of low
fluorescence. Of note, the thrombocytopenic animals
also had a significant proportion of platelets (>10%)
within the zone of very high intensity of fluorescence
(Figure 3 (Gate R2), M2 region of left panels) and high
FSC and high SSC, while the healthy ones always had at
the most, 4% of platelets with these characteristics (Fig-
ure 3 (Gate R2), M2 region of right panels, and Table 2).
The R3 gate defined platelets with low FSC (<101) and
medium SSC (101-102), which represent very small plate-
Figure 3
Flow cytometric representation of morphological and fluorescent 1 (FL 1) signal of platelets. Histogram plots of
the fluorescence signal carried by platelets delineated within gate R2. PaIg was determined by performing histogram analysis of
the fluorescence carried by the platelets gated into R2. Markers M1, M2, M3 and M4 are identical to the displayed in Figure 2
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lets or platelet derived microparticles (Table 3). This
fraction was found significantly enhanced in one of the
thrombocytopenic horses (Horse 1) as is shown in figure
1 and Table 3. Interestingly, some of these platelets still
carry very high fluorescence (Figure 4 (Gate R3), Horse 1
panel-M2 region) (Table 3 and Table 4, MFI of R3). Of
note, both horses with thrombocytopenia have a higher
number of platelets in R2, but one horse had the higher
percentage of strongly fluorescent platelets in R2 and
low number of microparticles while the other one had an
inverted pattern consisting of less percentage of fluores-
cent platelets in R2 but higher number of fluorescent mi-
croparticles (Figure 5, Table 2 and Table 4). These
findings raise the possibility that the antibodies might
bind to the gigantic platelets found in R2 (circulating
large platelets or megakaryocytes or even platelet aggre-
gates) and remain associated to them all the way through
the pathological fragmentation process until they turn
down into microparticles (Figure 5, Figure 7 and Table
3). It has been described that patients with IMT showed
an increased percentage of both: microthrombocytes or
platelet fragments and megathrombocytes [15,16], a
finding similar to the observed with the two IMT horses
described in this report.
Follow up of the thrombocytopenic horses was only fea-
sible in horse 1. Sample 1a defines the sample obtained
before treatment. Sample 1b was obtained after finishing
the first cycle of treatment. It is clear that there was im-
provement in the flow profile since the high fluorescent
microthrombocytes or platelet fragments almost disap-
peared and the number of megathrombocytes decreased
but they did not disappear (Table 3 and 4). Further fol-
low up showed that the number of platelets in gate R2 in-
Figure 4
Flow cytometric representation of morphological and fluorescent 1 (FL 1) signal of platelets. Histogram plots of
the fluorescence signal carried by platelets delineated within gate R3. PaIg was determined by performing histogram analysis of
the fluorescence carried by the platelets gated into R3. Markers M1, M2, M3 and M4 are identical to the displayed in Figure 2.
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creased almost to normal levels (Figure 6 and 7 and table
3 and 4). For the sake of comparison, included is the pro-
tocol for analyzing and defining the gates and markers in
an unstained sample of a healthy horse. There is clearly
a cloud of platelets in G1 but almost nothing at gate G2
and G3 (Figure 8). Furthermore, the level of autofluores-
cence in unstained platelets is minimal and the signal
FL1 is less than 10 in the FL-1 log scale (Figure 8).
In this study, we evaluated a flow cytometric assay for
detecting platelet-bound immunoglobulin G in horses.
In comparison to the standard approach developed by
George JN to study human platelets [10,13], this assay is
easy to perform, inexpensive, and noninvasive and does
not require that platelets from normal subjects be in-
cluded in each assay. Together with clinical examination,
laboratory tests and bone marrow evaluation, the test de-
scribed in this report provides important information
that may help to define the cause of the disease and the
management of clinical patients and prognosis [12].
Thus, this study provides clear evidence that the anti-
bodies (IgG isotype) are bound to abnormal platelets in
horses with thrombocytopenia but the role of such anti-
bodies in the pathogenesis of the disease remains to be
addressed in further studies. However, based on the fact
that the animals with thrombocytopenia displayed i) in-
creased number of platelets with high FSC and high SSC
and that ii) a significant number (9.8% for horse 1a and
11.9% for horse 2) of those gigantic platelets displayed
higher fluorescent signal (IgG bound as determined by
Figure 5
Flow cytometric Density plot representation of platelets from Thrombocytopenic and normal horses. The two
upper rows display the set of panels (FSC × FL1 plots of platelets) from two healthy horses while the two lower rows display
the set of panels (FSC × FL1 plots of platelets) from two thrombocytopenic horses. The corresponding density plot (FSC ×
FL1) within the gates are shown in the columns. No gate (external left column). Gate R1 (internal left column. Gate R2 (inter-
nal right column). Gate R3 (external right column).
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adding the % of platelets in M2 and M3-Table 2), it is
tempting to hypothesize that such antibodies play a sig-
nificant role in the earlier stages of the platelet matura-
tion/production and may contribute to the generation of
microparticles in later stages of the disease [17,18]. Fur-
ther investigations with human subjects affected of AIT
remain to be performed in order to expand the scope and
validate within other mammals the findings of this study.
Figure 6
Flow cytometric representation of morphological and fluorescent 1 (FL 1) signal of platelets of Horse 1 three
weeks after new episode of thrombocytopenia and comparison with four healthy horses. Figure 6A. Density plots
of ungated platelets from a thrombocytopenic and four normal horses. A set of panels displaying the FSC × SSC density plot of
platelets derived from four healthy horses (Horse 6-9) are showed. The upper left panel of figure 6A represents the FSC × SSC
density plots of thrombocytopenic Horse 1c. The gates R1, R2 and R3 are showed in each panel. Figure 6B. Histogram plots of
the fluorescence signal carried by platelets delimited within gate R1.The evaluation of the presence of platelet associated IgG
(PaIg) was determined by performing histogram analysis of the fluorescence carried by the platelets gated into R1. Markers M1,
M2, M3 and M4 were drawn within the histogram plots. Markers are identical to the displayed in Figure 2 Figure 6C. Histogram
plots of the fluorescence signal carried by platelets delimited within gate R2. PaIg was determined by performing histogram
analysis of the fluorescence carried by the platelets gated into R2. Markers M1, M2, M3 and M4 are identical to the displayed in
Figure 3 Figure 6D. Histogram plots of the fluorescence signal carried by platelets delimited within gate R3. PaIg was deter-
mined by performing histogram analysis of the fluorescence carried by the platelets gated into R3. Markers M1, M2, M3 and M4
are identical to the displayed in Figure 4.
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Figure 7
Flow cytometric Density plot representation of platelets from a Thrombocytopenic horse before treatment
and during follow up. The three lower rows display the set of panels (FSC × FL1 plots of platelets) from a thrombocyto-
penic horse. The lower row represents the sample labeled Horse 1a. This sample was taken prior to treatment, while the two
middle rows display the set of panels (FSC × FL1 plots of platelets) from the follow up. The date is listed. A healthy horse is dis-
played in the upper row. The corresponding density plot (FSC × FL1) within the gates are showed in the columns. No Gate
(external left column). Gate R1 (internal left column). Gate R2 (internal right column). Gate R3 (external right column).
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